Compositions and Methods of Increasing RNA Translation

Case ID:
C18083

Value Proposition

  • mRNA use for therapeutic purposes has proven useful in treating a wide array of diseases.
  • Major challenges of mRNA therapies include immunogenicity, poor expression, and low stability.
  • This therapy contains modifications improving mRNA stability, efficiency, and immunogenicity.
  • This technology allows for the translation of almost any exogenously delivered mRNA therapy.

 

Unmet Need

  • mRNA therapeutics are becoming increasingly utilized in the medical space due to their specificity and ability to treat a wide array of diseases. While there are many benefits to mRNA-based therapeutics, there is a growing need for therapeutics designed to limit undesired immunogenicity, increase transfection efficiency, and increase stability of mRNA therapeutic for greater therapeutic efficacy.

 

 

Technology Description

  • Reported here is SPARX (Sequence Promoting the Amplification of RNA Expression) an mRNA aptamer-based therapeutic design approach aiming to tackle the typical limitations of mRNA-based therapeutics. Through modifications on the aptamer, SPARX is capable of reducing immunogenicity, increasing mRNA stability, and promoting increased expression of exogenous mRNA through optimal ribosomal binding.  Altogether, SPARX has the potential to increase efficiency, stability, and efficacy of mRNA-based therapeutics.

 

Stage of Development

  • In vitro proof of concept
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
RNA Aptamer for Enhancing the Expression of Synthetic mRNA Vaccines and Therapies PRO: Provisional United States 63/740,390   12/31/2024     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum